Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083751 | 0.95 | PLK1 (0.36) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3231101 | 0.82 | PLK1 (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3231088 | 0.82 | PLK1 (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL14952424 | 0.81 | PLK1 (0.36) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL5936768 | 0.81 | PLK1 (0.46) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL31098116 | 0.81 | PLK1 (0.36) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL14952425 | 0.78 | RPS6KA3 (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL10453154 | 0.77 | KDM4E (0.38) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL1288242 | 0.77 | PLK1 (0.49) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL1288243 | 0.77 | PLK1 (0.49) | KDM4EMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | KDM4E 1150/4885MEN1 1136/4885ALDH1A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.